Upper-body morbidity after breast cancer: Incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care by Hayes, Sandi et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Hayes, Sandra C., Johansson, Karin, Stout, Nicole L., Prosnitz, Robert
G., Armer, Jane M., Gabram, Sheryl, & Schmitz, Kathryn H. (2012) Upper-
body morbidity after breast cancer : incidence and evidence for evaluation,
prevention, and management within a prospective surveillance model of
care. Cancer, 118(S8), pp. 2237-2249.
This file was downloaded from: http://eprints.qut.edu.au/56899/
c© Copyright 2012 John Wiley & Sons, Inc
The definitive version is available at www3.interscience.wiley.com
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.1002/cncr.27467
  p. 1 
Title: 
Upper-body morbidity following breast cancer: incidence and evidence for evaluation, 
prevention and management within a prospective surveillance model of care 
 
Running title:  
Upper-body morbidity following breast cancer 
 
Authors: 
Sandra C Hayes, Karin Johansson, Nicole Stout, Robert Prosnitz, Jane M Armer, Sheryl 
Gabram, Kathryn H Schmitz 
 
Sandra C Hayes:  PhD; Queensland University of Technology, Institute of Health and 
Biomedical Innovation, School of Public Health, Brisbane, Australia. 
Karin Johansson: PT, PhD; Department of Oncology, Lund University Hospital, Sweden. 
Nicole Stout: MPT; CLT-LANA Breast Care Center, Walter Reed National Military 
Medical Center, Bethesda, MD. 
Robert Prosnitz: MD, MPH; Department of Radiation Oncology, University of 
Pennsylvania, Philadelphia, PA. 
Jane M Armer: RN, PhD; Sinclair School of Nursing, University of Missouri, Columbia 
MO. 
Sheryl Gabram: MD, MBA; Department of Surgery, Winship Cancer Institute of Emory 
University, Atlanta, GA. 
Kathryn H Schmitz: PhD; Department of Biostatistics and Epidemiology, University of 
Pennsylvania, Philadelphia, PA. 
 
Corresponding author: 
Sandra C Hayes 
Queensland University of Technology, School of Public Health, Institute of Health and 
Biomedical Innovation, Victoria Park Rd, Kelvin Grove, Brisbane, Queensland, 
Australia, 4059; phone: +617 3138 9645; fax: +617 3138 3130 email: 
sc.hayes@qut.edu.au 
  p. 2 
 
Total number of pages: 27; number of tables: 2; word count: 5023 
 
Acknowledgements:  
The authors wish to acknowledge all participants of the think tank whose comments 
enriched discussions and clarified rehabilitation issues faced by women with breast 
cancer.  We would also like to acknowledge the contributions of Tracey Di Sipio and 
Sheree Rye in undertaking the review of the literature and extraction of data necessary for 
completing this manuscript.  
 
Funding for this manuscript: 
The lead author’s fellowship position is supported by the National Breast Cancer 
Foundation, Australia. 
 
Disclaimer: 
The views expressed in this article are those of the authors(s) and do not reflect the 
official positions or views of the Department of Defense, the US Navy nor the US 
Government. 
 
Financial disclosers: 
None to disclose 
 
Condensed Abstract: 
Upper-body morbidity, including lymphedema, is common following breast cancer and 
may persist beyond the active treatment period.  Integration of a prospective surveillance 
model into breast cancer care has the potential to optimize early diagnosis and treatment 
of upper-body morbidity, and in doing so will enhance women’s ability to participate in 
daily activities and their quality of life.   
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Abstract: 
The purpose of this paper is to review the incidence of upper-body morbidity (arm and 
breast symptoms, impairments and lymphedema), methods for diagnosis, and prevention 
and treatment strategies.  It was also the purpose to highlight the evidence-base for 
integration of prospective surveillance for upper-body morbidity within standard clinical 
care of women with breast cancer.  Between 10-64% of women report upper-body 
symptoms between 6-months to 3 years post-breast cancer and approximately 20% 
develop lymphedema.  Symptoms remain common into longer-term survivorship and 
while lymphedema may be transient for some, those who present with mild lymphedema 
are at increased risk of developing moderate-severe lymphedema.  The etiology of 
morbidity seems to be multifactorial, with the most consistent risk factors being those 
associated with extent of treatment.  However, known risk factors cannot reliably 
distinguish between those who will and will not develop upper-body morbidity.  Upper-
body morbidity may be treatable with physical therapy.  There is also evidence in support 
of integrating regular surveillance for upper-body morbidity into the routine care 
provided to women with breast cancer, with early diagnosis potentially contributing to 
more effective management and prevention of progression of these conditions.   
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I. Overview of the epidemiology of upper-body morbidity 
Upper-body morbidity following breast cancer is typically characterized by the presence 
of sensory or motor symptoms and impairments such as pain, weakness, tightness, poor 
range of motion, nerve palsies, altered movement patterns or muscle recruitment, 
numbness, or swelling in the shoulder, arm and/or breast of the affected side.  Upper-
body morbidity is typically associated with alterations in the use and function of the 
upper-body and adverse physical, psychosocial and social ramifications that profoundly 
influence all aspects of daily life and hence quality of life (QoL).1-7 Arguably, 
lymphedema (swelling) is regarded as the most feared and problematic.5 The purpose of 
this paper is to review upper-body morbidity incidence and risk factors, methods for 
diagnosis, and prevention and treatment strategies.  The evidence-base for integration of 
prospective surveillance of upper-body morbidity within standard clinical care of women 
with breast cancer will also be highlighted. 
 
II. Incidence of upper-body morbidity post-breast cancer  
Upper-body symptoms and impairments 
Despite advances in breast cancer treatment methods that have led to less invasive 
surgical techniques, such as sentinel node biopsy,8-9 and more refined radiation 
techniques, such as intensity modulation,10-11 upper-body symptoms and impairments that 
impact function and quality of life remain common. Incidence of individual symptoms, 
such as pain and weakness, as well as nerve palsies, skin fragility, soft tissue fibrosis and 
inflammation have been the focus of prior research studies.12-21  
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  In the past 10 years, the presence of upper-body symptoms following breast cancer 
has been evaluated in more than 20 studies,2, 9, 22-41 including 7 cohort studies involving 
population-based samples (Table 1).22-24, 33-34, 42-43 A wide range in prevalence was 
reported across these studies, with higher rates generally observed in cohort studies 
compared with clinical trials.  Symptoms (which may have included any one or more of 
the following: weakness, stiffness, numbness, tingling, pain, poor range of motion, 
swelling) was assessed in these studies via self-report methods using validated or non-
validated questions.  The majority of studies assessed only a subset of the known 
symptoms reported by women with breast cancer (e.g., weakness, stiffness and tingling 
were rarely assessed) and it is plausible that the entire spectrum of possible upper-body 
symptoms that women may experience is yet to be fully understood. The inclusion of 
mild symptoms as being indicative of morbidity was variable.  At least 10%, but as many 
as 60% of women report at least one upper-body symptom at any point from 6-months to 
3-years post-breast cancer surgery (Table 1).  Pain (e.g., breast, axilla, myofascial pain) 
has possibly received the most attention of all symptoms, with its prevalence ranging 
from 12-51%.13-14  
 One challenge in drawing conclusions about the frequency of upper-body symptoms 
is that studies vary with regard to length of follow-up.  There are 2 population-based 
studies that have assessed upper-body symptoms beyond 3 years.  Results suggest similar 
prevalence between 4-5 years post-surgery (up to 56% of women report at least one 
symptom)24, 33 to that observed during 6 months to 3 years post-surgery.  Also, the 
presence of multiple symptoms is more common than having one symptom alone.  In a 
population-based, prospective cohort study of Australian women, the majority of those 
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reporting moderate-extreme symptoms report multiple symptoms between 6-18 months 
post-surgery (56-68% across time points).42  In this issue of Cancer, it is noted that at 6 
years post-diagnosis, over 50% of breast cancer survivors from that same Australian 
cohort report one or more upper-body symptom (see Schmitz et al in this supplement). 
Taken together, these results indicate that upper-body morbidity is common following 
breast cancer and remains common well beyond the treatment period.   
 
Lymphedema 
Lymphedema is caused by a disruption of the lymphatic system that in the initial stages, 
leads to the accumulation of fluid in the interstitial tissue space (that is, increases in 
extracellular fluid) and eventually clinically manifests as swelling of the arm, breast, 
shoulder, neck or torso.44 Later stages of lymphedema are characterized by deposition of 
fibrotic and adipose tissue.45 
It is well established that the chosen diagnostic method used to assess 
lymphedema influences the results found in observational studies.46-48 Bioimpedance 
spectroscopy assesses changes in extracellular fluid and has been shown to identify limb 
changes before clinical presentation of the condition and until the condition becomes 
non-pitting (fibrotic).49  Methods that assess limb size (such as water displacement, 
perometry or circumferences), with or without conversion of measure of size to limb 
volume, can detect non-pitting and pitting lymphedema of sufficient magnitude, but may 
be insensitive to early changes in extracellular fluid. Self-report methods (such as the 
Norman questionnaire,50 the Lymphedema Breast Cancer Questionnaire,51 the 
Lymphoedema Quality of Life Inventory,52 items from validated QoL-specific 
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questionnaires (such as FACTB+4,53 EORTC QLQ-C3054) or via non-validated 
questions) take into account perceived sensory and size changes, as well as presence and 
intensity of related symptoms. However, as demonstrated earlier, the presence of 
symptoms are common in women following breast cancer, and this is irrespective of 
lymphedema status.42  A study that used multiple measures to assess lymphedema status 
in women 6-months post-breast surgery found that 40% of those with objective 
lymphedema (defined by bioimpedance spectroscopy) did not self-report swelling, and 
40% of those without objective lymphedema did.48  A USA-based study similarly found 
that breast cancer survivors met four different lymphedema criteria at various rates of 
occurrence (43-94%), with 11% meeting all four criteria and 84% meeting at least one 
criterion.55 All clinical measures, when undertaken by trained personnel, and the 
validated self-report measures have proven repeatability.  However, each method’s 
accuracy in diagnosing cases (as well as avoiding misclassification of non-cases) is 
dependent on which other diagnostic method it is being compared against.56  As yet, there 
is no agreement of which method, or combination of methods, reflects the most accurate 
diagnostic tool.   
Given the variation in available diagnostic methods, which ultimately assess 
different attributes of lymphedema, it is not surprising that the extent of the public health 
burden posed by secondary lymphedema has long been clouded by wide variations in 
reported incidence. Reported rates in women following treatment for breast cancer have 
varied from 6-80%.57  Also contributing to the wide variation in incidence is timing of 
measurement (2 months to 20 years post-breast cancer) and the type of cohort evaluated 
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(may have included only those who underwent axillary dissection and/or radiation 
therapy).   
In the past five years, 11 prospectively-designed studies (graded as Level II 
prognostic studies according to the National Health and Medical Research Council, 
Australia)58 have reported incidence estimates of secondary lymphedema following 
breast cancer (Table 2). These studies used objective diagnostic criteria and included 
samples generally representative of the larger breast cancer population. Median reported 
incidence in these 11 studies was 20% (range, 0-94%).  It therefore seems plausible to 
suggest that from six months post-surgery, approximately one in five patients treated for 
breast cancer will experience secondary lymphedema. The median rate appears to 
increase with longer follow-up, escalating from 11% up to 12 months to 36% beyond 12 
months. Findings also suggest that 45-60% of patients with long-term secondary 
lymphedema present with the condition by 6 months post-surgery,59-60 while 70-80% 
present by 12 months post-surgery.60-61  Consequently, it seems clear that despite 
advances in breast cancer treatment over the past decade, lymphedema continues to be a 
common concern, with new cases presenting well beyond the active treatment period.  
Lymphedema is regarded as a persistent or chronic condition.  However, results 
from 2 prospective studies, one using an objective measure61 of lymphedema status and 
the other a validated self-report measure,62 suggests this may not be the case for all 
women.  The studies demonstrated that up to 60% of women with evidence of 
lymphedema had ‘acute’ lymphedema (lasting no more than 5 months), dissipating with 
or without treatment (although commencement of, or adherence to, treatment was not 
formally assessed).  Between 30-40% had chronic and/or progressive lymphedema and 
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between 15-22% had fluctuating lymphedema, which may have included intermittent 
periods without symptoms.  Therefore, lymphedema seems transitory for some, with or 
without treatment, and long-term for others, with or without intermittent periods of relief.   
This variable nature of lymphedema may further contribute to the wide range of 
incidence reported throughout the literature.  Importantly though, those who present with 
mild lymphedema are at increased risk (up to 3 times increased risk) of developing 
moderate to severe lymphedema.62-63    
 
III. Identifying known risk factors for the development or exacerbation of upper-body 
morbidity  
The extent of upper-body morbidity following treatment for breast cancer has been a 
major driving force in the quest for identifying less invasive treatment strategies that 
could reduce morbidity without adversely influencing survival.26 An established and 
growing literature base clearly demonstrates that upper-body morbidity is higher among 
those who undertake more invasive treatment options, such as axillary dissection versus 
sentinel node biopsy, mastectomy versus breast-conserving surgery, and/or radiation to 
the breast/chest wall and regional nodes versus radiation to the breast/chest wall only.31, 
64-68   
Injury to the intercostal brachial or thoracodorsal nerve may occur with axillary 
lymph node dissection and is a major cause of axillary paresthesia, muscular dysfunction 
(e.g., dysfunction of the serratus anterior or latissimus dorsi) and pain.14,69  Nerve injuries 
may resolve over several months without therapeutic intervention; however, the 
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implications to muscle recruitment pattern, flow-on effect to surrounding musculature 
and use of the arm may be permanently altered without intervention.70 
Research on radiation-induced upper-body morbidity has uncovered a wide range 
of issues, including skin fragility,16-17 fibrosis and inflammatory changes to the soft tissue 
in the irradiated area,17, 71 as well as brachial plexopathies and other neuropathic 
impairments that may lead to sensory and motor changes.72-74 Radiation-induced soft 
tissue fibrosis is generally mild, and chronic radiation fibrosis is rare.  Nonetheless, 
chronic fibrosis is significant and problematic and unfortunately its development and 
effective management is not well understood. Clinically, it is noted that fibrosis 
contributes to diminished joint mobility and may foster short and potentially long-term 
shoulder, scapulae and postural changes.  Historically, due to poor shielding techniques 
and inadvertent exposure of the plexus to the radiation beam, radiation therapy also 
contributed to severe brachial plexopathies and neuropathic impairments.72 However, 
modern techniques protect the brachial plexus and prevent inadvertent nerve damage.  
Brachial plexopathy is now considered rare, even in women for whom the supraclavicular 
and axillary regions are treated.  Nonetheless, when it occurs, sensory and motor changes 
in the upper-body present, with severe cases experiencing paralysis.  Results from 2 
studies with over two decades of follow-up73-74 have shown that the rate of radiation-
induced soft tissue damage and neuropathies was estimated to be 1% per year, netting a 
cumulative incidence of near 20% by 20 years post-therapy.73-74  While incidence 
estimate may no longer be representative of women treated with radiation therapy for 
breast cancer today, they underscore the need for long-term follow-up. 
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The contribution of diagnostic factors (including tumor size, positive lymph node 
status, stage of cancer), physiological characteristics (such as lymphatic transport, vein 
wall movement and venous anatomy and flow), and patient and behavioral characteristics 
(including body mass index, age, treatment on the dominant side, physical activity levels 
and socioeconomic status) with respect to development of lymphedema have also been 
evaluated.57   To date, results derived from prospective cohort studies suggest that stage 
of disease, node status and adjuvant therapy other than radiation therapy does not impact 
lymphedema risk.57 However, as adjuvant therapies continue to evolve, their relationship 
with lymphedema risk will require continued exploration.   
More work is also required to better understand the physiological changes 
associated with increased risk of lymphedema.  Higher body mass index has long been 
considered a risk factor for lymphedema.60, 75-80  However, when findings from more 
recent studies are considered the relationship is less clear, with several prospective cohort 
studies demonstrating no relationship between higher body mass index and lymphedema 
risk.9, 61, 81 Nonetheless, higher body mass index has never been associated with reduced 
risk and the importance of maintaining healthy body weight in relation to other breast 
cancer outcomes is clear (see Demark-Wahnefried et al in this supplement).  The 
relationship between age and risk of lymphedema is mixed, with some studies showing 
no relationship,9, 60, 81 while others showing increased risk with increasing age.61, 82-83  
Race, upper-body function61 and physical activity levels61, 84-85 may also be associated 
with lymphedema risk; specifically, being African American,86 having lower than 
average upper-body function and being sedentary has been associated with increased 
lymphedema risk.61 Finally, those with lymphedema are more likely to report multiple 
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upper-body symptoms, and the presence of symptoms has been significantly associated 
with subsequent lymphedema development.27  
While a number of risk factors for the development of lymphedema have been 
identified, at present it is not possible to accurately predict who will and will not develop 
this condition.87  In one prospective, population-based study of 287 newly diagnosed 
breast cancer patients, 12 key treatment-related, personal and behavioural characteristics 
were identified as important factors with respect to lymphedema risk.  However, together 
they explained no more than 35% of the variation between those who did and did not 
develop lymphedema.42 
 
IV. Methods to detect upper-body morbidity 
Self-report and objective methods available for detecting and monitoring lymphedema 
were reviewed in an earlier section (section II).  When deciding which assessment 
method(s) are optimal, several factors must be considered, such as the sensitivity and 
specificity of the measure, whether the measure has been shown to detect ‘subclinical’ 
lymphedema (before patients report symptoms) and whether the measure is affordable, 
transportable, practical for clinic use, non-invasive and time efficient.88 Given different 
methods assess different elements of lymphedema, the use of multiple assessment 
methods is ideal, particularly for tracking change over time.    
Shoulder function can also be evaluated using any one or more of self-report or 
clinical methods. Validated questionnaires such as the BREAST-Q89 and the Disability of 
the Arm, Shoulder and Hand questionnaire90 provide comprehensive self-report 
assessment of upper-body morbidity, as well as the presence and severity of specific 
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symptoms.  Standardized procedures exist for the assessment of active and passive 
shoulder range of motion in all planes using goniometry,91 while strength and function 
can be assessed using isometric and isokinetic dynamometry and/or maximal or 
submaximal performance of set tasks/exercises using the repetition maximum method.92  
However, upper-body assessment may also involve palpation of areas, particularly in the 
assessment of myofascial pain93 and tightness.31  Visual inspection of posture of the 
whole body, as well as the upper-body in routine position, performance of spontaneous 
activities and planned tasks provides additional information regarding upper-body 
function.94 Finally, it is noted that a clinical assessment involves understanding existing 
function in addition to revealing specific impairments.94 
 
V. Evidence-based prevention and treatment strategies 
Prevention strategies for minimising upper-body morbidity have focused on the use of 
less invasive treatment methods when clinical presentation of the disease allows and the 
use of shoulder exercises after breast cancer surgery to optimise function.   The evidence 
base for prevention and treatment of upper-body morbidity is presented below. 
Upper-body symptoms and impairments  
Studies that have assessed the effectiveness of post-operative physical therapy contend 
that physical therapy is beneficial for upper-body function and does not cause any 
adverse effects.95-99 These studies have been limited in sample size.  In general, there is 
scant evidence base for the efficacy of rehabilitative (e.g. physical therapy) or exercise 
interventions to prevent or treat upper-body symptoms or shoulder dysfunction in breast 
cancer survivors beyond studies specific to lymphedema.  In the absence of a strong 
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evidence base, the commonly used clinical approach to treating several upper-body 
symptoms and impairments is outlined below. 
Standard physical therapy approaches to dealing with pain include gentle range of 
motion exercises, stretching, acupressure, myofascial stretching, as well as dry needle 
techniques.93  Patient education to identify positions or activities that alleviate the 
symptoms is important for self-care management and a gradual, progressive mobility 
program is encouraged.   Clinically, pain management often requires an ongoing, 
multidisciplinary approach to monitor changes with treatment and assess response to 
medication.  New onset pain or increasing pain may have additional etiologies including 
tumor infiltration of the brachial plexus or tumor recurrence.100  
Early assessment and intervention post-surgery, by way of education and shoulder 
exercises, is important to correct subtle treatment-related changes in scapulae position 
and stability that left untreated may lead to upper-body symptoms and impairments, and 
to also correct muscle recruitment imbalance.95, 101  Ongoing assessment and education is 
necessary to determine if tissue changes that may occur during and beyond the adjuvant 
treatment period, such as shortening of the pectoralis major, perpetuate existing, or lead 
to the development of, upper-body morbidity.102 Range of motion exercises play a 
particularly important role during and after radiation treatment to enhance tissue 
extensibility and promote normal movement patterns101 and should be encouraged 
indefinitely to avoid tissue contracture and concomitant alterations to the joint mechanics 
of the shoulder.  Further, manual techniques such as myofascial release have also been 
considered useful in improving tissue extensibility and enhancing mobility.103 
Lymphedema 
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In the prevention of lymphedema, two randomized, controlled trials, one evaluating the 
effectiveness of a ‘physiotherapy management care plan’ (including education and 
progressive exercises)104 and the other evaluating a physical therapy program that 
included manual lymph drainage, massage of scar tissue and progressive exercises),105 
have demonstrated clinically relevant benefits.  Both studies showed a higher proportion 
of women with lymphedema in the comparison group, compared with the physical 
therapy intervention group.  The trial that included manual lymph drainage as part of the 
intervention demonstrated that the risk ratio for developing lymphedema in the 
intervention group was 0.25 (95% CI: 1.10, 0.79) compared with the control group.  
Results from another randomized, controlled trial suggest that delayed (7 days post-
operative) versus early (within 48 hours post-operative) commencement of shoulder 
exercises was more favourable with respect to lymphedema development.106 
Notably though, the commonly available risk-reducing lymphedema guidelines 
are loosely based on what will minimise the production of lymph, which is directly 
proportional to blood flow, and what will minimise blockage to lymph transport.107 For 
example, heat, infections and exercise may increase blood flow and therefore lymph 
production in the arm, while tight clothing may obstruct lymph flow.107  Unfortunately, 
the evidence to support or refute these guidelines is scarce.  There is a clear need for 
well-designed, population-based, prospective studies to investigate the potential causal 
relationship between participating in ‘risky’ behaviours and subsequent lymphedema 
development.  Until this occurs, it seems reasonable for prevention strategies to be 
discussed with women, especially in the context of encouraging healthy behaviours, such 
as participation in regular exercise and maintaining healthy body weight.  In fact, results 
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from a prospective, population-based cohort study as well as a randomized, controlled 
trial suggest that participating in regular exercise following breast cancer may prevent the 
development of lymphedema.61, 108  
The goals of secondary lymphedema management include reduction of swelling, 
prevention of progression, alleviation of associated symptoms, prevention of infection 
and improvement in function and quality of life.  Treatment options can be broadly 
categorised as conservative, surgical, pharmacologic or alternative.  The evidence behind 
lymphedema treatment options has previously been reviewed.57, 109-110  Findings from 
these reviews, as well as results from treatment studies published in the last 3 years are 
summarised below to provide an overview of the evidence for various lymphedema 
treatment options.   
Treatment effects (limb volume reductions) for conservative treatment options are 
in the range of 8-66%, with several studies reporting continued reductions over 6-12 
months follow up.  Volume reductions achieved by manual lymph drainage or pneumatic 
pumps tended to be higher when therapy was combined with other conservative treatment 
options, such as compression and massage.  However, compression alone or in 
combination with other treatment, led to volume reductions of 4-60% measured at 4 
weeks to 6 months follow up. When reported, response rates varied between 28-66%, and 
characteristics of those lost to follow-up were typically not reported.  Lack of reference to 
clinically meaningful changes, questionable representativeness of sample, potential bias 
caused by significant numbers lost to follow-up (likely more so for those not 
experiencing treatment effects), and lack of control group and/or adjustment for potential 
confounders severely influences the strength of these findings.  Nonetheless, there is a 
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growing body of low-level evidence in support of these therapies, which ultimately form 
the primary method currently used to treat lymphedema.111 
Low-level laser therapy (light source treatment that generates light of a single 
wavelength, but does not emit heat, sound or vibration) has been used as a form of 
lymphedema treatment since 1995 in some countries, but only received FDA approval in 
the USA in 2007.112  Research in the area is limited and should be regarded as 
encouraging but preliminary.  A randomised trial of low-level laser therapy (LTU-904 
hand-held laser, RianCorp) in women with post-mastectomy lymphedema reported a 
trend towards reductions in arm volumes over time following two cycles of treatments, 
but that despite these reductions, volumes at the 3 month follow-up were not statistically 
different from baseline values.113  Other studies have reported 16-79% volume reductions 
(using various hand-held laser devices), but compare changes to another treatment 
group114 or lack a control group.112, 115-116   
There have been several investigations evaluating the role of exercise on 
lymphedema status, with varying methodological qualities.  Randomised, controlled trials 
have evaluated the role of combined exercise and relaxation therapy,117 aqua therapy,118 
combined aerobic- and resistance-based exercise119 and weight training.120-121  Sample 
size within these studies ranged between 31-141, intervention duration ranged from 8 
weeks to 12 months and lymphedema status as well as other physical and psychosocial 
outcomes were typically assessed.  All studies demonstrated that exercise did not 
exacerbate existing lymphedema and had positive effects on other outcomes influencing 
function and quality of life.  The largest of the trials, evaluating a 12-month weight-
training intervention (n=141), also demonstrated significant improvements in 
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lymphedema-associated symptom severity, as well as reduced lymphedema 
exacerbations, compared with the control group.121  The results of these trials support the 
use of progressive exercise, with supervision at least in the earlier part of the intervention, 
in optimising upper-body outcomes.  Current lymphedema prevention guidelines have 
been labelled ‘risk averse’ and may therefore encourage women to avoid use of their 
arms and bodies.  Results from exercise intervention studies involving women with 
lymphedema highlight the need for encouragement rather than avoidance of participation 
in physical activity following breast cancer.122   
The association between body weight and lymphedema risk has led to two studies 
investigating the potential for weight-reduction strategies to reduce lymphedema.123-124 
While results suggest that weight-reducing strategies may be useful in the management of 
lymphedema, further studies utilising larger sample sizes and lymphedema assessment 
methods that are not sensitive to weight changes are warranted (e.g., bioelectrical 
impedance spectroscopy).  
The use of medications to manage secondary lymphedema is of continued interest 
with emphasis to date being placed on benzopyrones and selenium compounds. 
Systematic reviews of the literature evaluating the use of these compounds in 
lymphedema management report that there is no evidence in support of their use.125-126 
More recently, a randomized, controlled study of 12 months treatment with pentoxifylline 
(which is used to improve blood flow through peripheral blood vessels) and vitamin E for 
the prevention of radiation-induced side effects in breast cancer patients (n=83), showed 
increases in arm volume in the control group but no change in the intervention group.127    
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Surgery for lymphedema includes debulking procedures to remove excess skin 
and subcutaneous tissue (e.g., liposuction) or the creation of new pathways for draining 
lymph (e.g., microsurgery, lymphatic-venous anastomosis).  Surgery is typically only 
recommended when conservative treatment options have failed to be effective, and 
lymphedema is chronic and pitting.  Although limited by study design (comparative 
studies without concurrent controls or case series) and small sample size, excellent results 
from studies evaluating liposuction128-130 and lymphatic vessel-isolated vein 
anastomosis131-132 have been reported, with complete resolution of excess limb volume, in 
addition to improvements in function and quality of life, being reported in several 
liposuction studies.128-130  The potential for scarring and other complications, as well as 
the need for continued use of compression garments following surgery, restricts the use 
of this treatment to a specific subset of women with relatively severe lymphedema who 
experience no response to conservative treatment.    
There is significant room for improvement in studies evaluating treatment for 
lymphedema.  Weak designs continue to influence the strength of the findings reported 
and there is high potential for over-reporting of treatment effects. Despite the need for 
more research into effective lymphedema treatment strategies, a number of treatment 
guidelines have been developed using the available evidence (Australia: National Breast 
and Ovarian Cancer Centre;133 Canada: Health Canadal;134 Europe: European Society for 
Breast Cancer Specialists;135 Sweden: Swedish Cancer Society;136 UK: National Institute 
for Health and Clinical Excellence, Clinical Resources Efficiency Support Team;137 
USA: National Lymphedema Network,138 Agency for Healthcare Research and 
Quality,139 Oncology Nursing Society140).   
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VI. Overview of the potential role that prospective surveillance would play in early 
identification and treatment, and whether there is a need to establish baseline 
measures  
Prospective surveillance may play an important role in the early detection and 
management of upper-body morbidity.  Within the broader breast cancer setting, 
impairments detected within the hospital setting are more likely to receive intervention, 
and this is particularly the case for low socioeconomic and minority status groups.141-142  
This may be as a consequence of increased scrutiny in the inpatient setting, the presence 
of critical pathways and/or the absence of specific access barriers.   
 More specific to upper-body morbidity though, results from a prospective, cohort 
study provide preliminary findings that support the integration of formal regular 
surveillance.143  In this study, lymphedema was identified in 43 of 196 women 
prospectively followed.  When an increase in limb volume of >3%, compared with pre-
operative volume (as assessed via perometry), was observed, compression garments were 
prescribed for 4 weeks.  Limb volumes were significantly reduced following the 
compression garment period.  Notably this was a cohort study and not a randomized, 
controlled treatment trial, limiting the strength of these findings.  Nonetheless, even if the 
3% limb volume change represented post-surgical swelling, which may spontaneously 
resolve, other research has reported higher risk for lymphedema at 6-9 months after 
surgery following post-surgical swelling.144  Further, others have also demonstrated that 
those with mild lymphedema are at greater risk of developing chronic and more severe 
lymphedema.62  Importantly, this prospective surveillance cohort study demonstrated that 
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regular assessment of upper-body morbidity (including preoperative measures) in a busy 
breast cancer clinic is possible, and that women were accepting of wearing compression 
garments for a 4-week period (although compliance with garment-wear was not tracked). 
This garment intervention is in contrast to many lymphedema treatment options being 
considered costly with respect to time, finances and lifestyle.57  These findings are 
supported by another prospective breast cancer cohort study, which spanned a 10-year 
period (n=292).145 Results from this study also demonstrated that the integration of 
regular surveillance is feasible and beneficial. Further, early diagnosis and treatment 
translated to more manageable lymphedema; 80% of those diagnosed with lymphedema 
throughout the follow-up period did not exceed 20% limb ratio volumes.   
 The personal costs associated with lymphedema are well known and documented, 
but data have only recently become available to demonstrate the potential overall 
financial costs.  Women with lymphedema following breast cancer have between 
$14,887-23,167 more medical costs when compared with women without 
lymphedema.146  Women with lymphedema also have more productive days lost than 
those without (73 versus 56 days).  So while there is a clear desire for minimizing over-
diagnosis of lymphedema, this must be balanced by what may be gained with early 
diagnosis and intervention.   
 The evidence presented throughout this paper provides support for the integration of 
regular surveillance of upper-body morbidity within standard breast cancer care, as is 
recommended by the prospective model published in this supplement (see Stout et al in 
this supplement).  Pre-operative assessment of upper-body morbidity is ideal, particularly 
for bilateral breast cancer cases; however, pre-operative assessment is not ‘true’ baseline, 
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with the contribution of the cancer to upper-body morbidity currently unknown.  Further, 
regular post-operative surveillance can still be successful in the absence of pre-operative 
measures.  For unilateral breast cancer, presence and severity of upper-body symptoms, 
impairments and lymphedema can be compared with the contralateral limb, and for some 
lymphedema measures, such as bioimpedance spectroscopy, comparisons can be made 
with the lower-limb in the absence of an unaffected upper-limb.147  Long-term follow-up 
after breast cancer has merit due to the observations that physical impairments may 
persist for years after treatment (see Schmitz et al in this supplement) and that some types 
of upper-body morbidities (e.g. radiation damage) may persist for decades after 
treatment.72-73	
Comprehensive assessment of upper-body morbidity, using clinical and self-
report methods is ideal, although may be impractical to administer in a busy clinic 
setting.  A possible solution may be to ensure comprehensive assessment occurs in the 
first instance (pre-operative and/or first post-operative assessment), with subsequent 
reliance on one or select method(s) for follow-up measurements, with adverse changes in 
self-report symptoms or the clinical measure dictating a subsequent more comprehensive 
assessment. Regularity of the measurement may be variable within treating centres and 
scheduled among normal post-operative, adjuvant treatment or post-adjuvant treatment 
visits.  Monthly to once every three months seems a reasonable surveillance interval, 
through to 12 months post-surgery, with less regular surveillance occurring beyond that 
period.  Given that lymphedema may be transient, fluctuating or chronic, consideration 
may be given to increasing regularity of surveillance when clinical evidence of the 
condition presents or patients self-report change in symptoms, and initiation of treatment 
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only after a predefined threshold (volume or time) is met.  Also, diagnosis of 
lymphedema within the first three months post-surgery or radiation is cautioned, as there 
is the risk of misclassifying normal post-treatment swelling.   Surveillance should be 
supplemented with patient education on early signs and symptoms of upper-body 
morbidity, in particular progression of severity of concerns.148  
 
VI. Summary 
Upper-body morbidity is common following breast cancer and although more extensive 
treatment has been consistently linked with higher incidence of morbidity, morbidity 
remains common despite the introduction of less invasive treatment options.  Upper-body 
symptoms, impairments and lymphedema typically present within the first 12 months 
following breast surgery (although cases can present years later), and as such, integration 
of regular surveillance into standard breast cancer care is considered appropriate and has 
been shown to be feasible.  Participation in regular and progressive physical activity 
following a breast cancer diagnosis may optimize function and quality of life, as well as 
minimize upper-body morbidity.  Upper-body morbidity seems amenable to physical 
therapies, with early diagnosis likely facilitating more effective treatment, as well as 
prevention of progression.   
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Table 1: Prevalence of upper-body symptoms reported by prospective, population-based cohort studies 
   Months post breast cancer diagnosis/surgery 
(Any one symptom prevalencea) 
Study 
Sample size 
(n) 
(country) 
Symptoms  
assessed 
6 
(10-53%) 
12 
(10-61%) 
18 
(10-44%) 
24 
(21-66%) 
36 
(19-54%) 
1. Albert et al (2006)22 389 
(Germany) 
swelling, poor ROM, 
pain 
27%% 19% 20% 21% 19% 
2. Arndt et al (2006)23 314 
(Germany) 
swelling, poor ROM, 
pain 
 24-30%    
3. Engel et al (2003)24 990 
(Germany) 
swelling, poor ROM  47%  44% 40% 
4. McCredie et al (2001)33 809 
(Australia) 
stiffness, swelling, 
numbness, pain 
 16-61%  21-66% 22-54% 
5. Paskett et al (2007)34 622 
(USA) 
swelling 20% 36% 44% 48% 54% 
6. Hayes et al (2010)42 285 
(Australia) 
tingling, weakness, 
pain, poor ROM, 
numbness, stiffness, 
swelling 
10-29% 10-22% 10-19%   
7. Janz et al (2007)43 1372 
(USA) 
breast, arm/shoulder 
pain 
46-53%     
a studies measured at least one of the following symptoms: tingling, weakness, pain, poor range of movement (ROM), numbness, stiffness, 
swelling; may have included mild symptoms and used various self-report methods including items from quality of life questionnaires or 
unvalidated items.  
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Table 2: Reported incidence of secondary lymphedema (objectively measured) in prospectively-designed breast cancer cohort 
studies published between 20072011  
Country and study 
Sample 
size Method of diagnosis 
Reported incidence post-surgery (%) 
6-month PS 12-month PS 18-month+ PS 
Australia    
Hayes et al (2008)56 211 BIS, >3SD than 
normative data, circ, 
>5cm differenceb 
11% 8-11% 12-15%
Belgium    
Devoogdt et al (2011)149 49 circ, >10% differenceb  18%
Canada    
Helyer et al (2009)150 137 per, >200cc differenceb  12%
Thomas-MacLean et al 
(2008)38 
347 circ, 3 definitions of 
differenceb 
 9-16%
England    
Bennett Britton et al (2007)151 50 circ, >10% differenceb  11% 28%
Korea    
Yang et al (2010)41 191 circ, >1cm differenceb 9% 12.0%
Norway    
Nesvold et al (2008)152 263 circ >2cm changea or 
>10% differenceb 
 RM=20% 
BCT=8%
Sweden    
Celebioglu et al (2007)153 60 per, >10% differenceb  SNB=0% 
ALND=20%
United States of America    
Armer et al (2010)154 213 circ, >2cm changea, per 
>200mL or >10% 
changea 
11-44% 22-66% 29-94%c
McLaughlin et al (2008)155 936 circ, >2cm changea  SLNB=5% 
ALND=16%
  p. 46 
Wernicke et al (2011)156 223 circ, 1cm differenceb  SLNB=5% 
ALND=35%
Abbreviations: PS, post-surgery; circ, circumferences; per, perometry; BIS, bioimpedance spectroscopy; RM, radical mastectomy; BCT, breast 
conserving treatment; a change from baseline, b difference between limbs, c range of occurrence rates of lymphedema measured at 18, 24, 30, 36, 
48, or 60 months (using 3 definitions). 
 
